US Drug Screening Market (2025-2030)
The US Drug Screening Market was valued at $4575.3 Million in 2025 and projected to reach to $9356.9 Million by 2030, representing a compound annual growth rate of 15.4%. The US drug screening market is poised for sustained growth through 2030, driven by escalating substance abuse concerns and mandatory workplace compliance requirements.
US Drug Screening Market Trends and Insights
- This growth reflects increasing regulatory requirements, workplace safety mandates, and rising substance abuse concerns across the US.
- The US market benefits from advanced healthcare infrastructure, widespread adoption of screening technologies, and strong enforcement of drug testing policies in both corporate and clinical settings. Driving the US market's acceleration is heightened demand for rapid, accurate testing solutions in the US workplace and healthcare sectors.
- The US continues to invest in innovative screening methodologies, including immunoassay, chromatography, and point-of-care testing platforms.
- Between 2025 and 2030, the US is expected to see significant adoption of automated screening systems and digital integration, positioning the country as a leader in drug screening technology and implementation standards..
Key Market Statistics
- CAGR (2025-2030) 15.4% CAGR
- Market Size, 2025 ~USD 4575.3 Million
- Forecast, 2030 ~USD 9356.9 Million
- Country US
US Drug Screening Market Overview
Market Valuation Growth :
The US drug screening market is valued at $4,575.3 million in 2025 and is projected to reach $9,356.9 million by 2030, representing a robust 15.4% CAGR over the forecast period.
Regulatory Drivers :
Stringent federal and state regulations, including DOT and SAMHSA mandates, are compelling employers across industries to implement comprehensive drug screening programs, fueling market expansion.
Workplace Safety Initiatives :
Increasing corporate focus on workplace safety and employee wellness programs is driving adoption of advanced drug screening technologies across manufacturing, transportation, and healthcare sectors in the US.
Technological Advancement :
Integration of rapid testing kits, immunoassay systems, and digital reporting platforms is enhancing screening efficiency and accuracy, supporting market growth across US healthcare and corporate facilities.
US Drug Screening Market Dynamics
- Federal initiatives addressing opioid addiction and illicit drug use are increasing demand for screening services across healthcare, law enforcement, and corporate sectors.
- The market benefits from advanced diagnostic infrastructure and widespread adoption of point-of-care testing technologies.
- Employers are increasingly investing in comprehensive screening programs to mitigate liability and ensure workplace safety.
- Technological innovations in rapid testing and digital integration are expected to further accelerate market penetration across diverse US industries and healthcare settings..
Related Ecosystem
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Abbott Laboratories
- Stryker Corporation
- Becton, Dickinson and Company
- JOHNSON & JOHNSON
Key Takeaways
- The US drug screening market will nearly double from $4,575.3M (2025) to $9,356.9M (2030), driven by regulatory compliance and workplace safety initiatives.
- The US maintains a 15.4% CAGR, reflecting strong demand for advanced testing technologies and automation in the US healthcare and corporate sectors.
- The US market is characterized by rapid adoption of point-of-care and digital screening solutions, enhancing efficiency across US testing facilities.
- Regulatory pressures and substance abuse prevention efforts continue to expand the addressable market for drug screening services throughout the US.
Drug Screening Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | ON-SITE TESTING SERVICES (Type) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 15.5% from 2025 to 2030 |
| Largest Segment | SERVICES (Offering) |
| Market Size Base Year (Billions) | ~USD 10.36 (2025) |
| Revenue Forecast (Billions) | ~USD 21.29 (2030) |
| Segments Covered | Offering, Type, Modality |
US Drug Screening Market Report Segmentation
3 segment dimensions are covered across the global market.
By Offering
- Products
- Services
By Type
- Analytical Instruments
- Assay Kits
- Breathalyzers
- Calibrators & Controls
- Chromatography Instruments
- Consumables
- Dip Cards
- Drug Testing Cassettes
- Drug Testing Cups
- Fuel-Cell Breathalyzers
- Immunoassay Analyzers
- Laboratory Testing Services
- On-Site Testing Services
- Oral Fluid Testing Devices
- Other Breathalyzers
- Other Consumables
- Rapid Testing Devices
- Sample Collection Devices
- Semiconductor Breathalyzers
- Urine Testing Devices
By Modality
- Benchtop Breathalyzers
- Handheld Breathalyzers
Target Audience
- Healthcare Providers & Laboratories : Need comprehensive market data to expand drug screening service offerings, optimize operational capacity, and capitalize on growing demand from corporate and clinical clients across the US.
- Corporate HR & Compliance Officers : Require market insights to benchmark screening programs, understand regulatory requirements, and make informed decisions about screening service providers and technology investments.
- Medical Device & Diagnostics Manufacturers : Need market sizing and growth forecasts to guide R&D investments, product launches, and market expansion strategies in the competitive US drug screening technology sector.
- Investment & Private Equity Firms : Seek validated market data and growth projections to evaluate investment opportunities in US drug screening companies and assess portfolio company performance potential.
- Government & Policy Agencies : Require market intelligence to inform substance abuse prevention policies, funding allocations, and regulatory frameworks supporting drug screening initiatives across US jurisdictions.
Key Companies in the US Drug Screening Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| UNILABS | Switzerland | Private Company | Laboratory Testing (Core & Specialised),Medical Imaging,Pathology & Centres of Excellence, |
| EIKEN CHEMICAL CO., LTD. | Japan | Public Company | Fecal immunochemical test (FIT) reagents for colorectal cancer screening,Microbiological reagents and media (clinical),Urinalysis test strips, |
| LABCORP | United States | Public Company | Routine and specialty diagnostics (core lab, women’s health, chronic disease programs),Gene-based, esoteric, and advanced disease-targeted testing,Biopharma Laboratory Services (pharma, biotech, device, CRO clients), |
| QUEST DIAGNOSTICS INCORPORATED | United States | Public Company | Routine and non-routine clinical testing,Advanced diagnostics and anatomic pathology,Life insurance risk assessment and workplace drug testing, |
| ABBOTT | United States | Public Company | Diagnostic Products,Medical Devices,Nutritional Products, |
| ORASURE TECHNOLOGIES INC. | United States | Public Company | Rapid infectious disease tests (HIV, HCV, syphilis, Ebola, COVID-19, SickleSCAN),Genomic saliva collection (Oragene, ORAcollect),Microbiome collection (OMNIgene GUT, SALIVA, Dx), |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| DRäGERWERK AG & CO. KGAA | Germany | Public Company | Acute-care capital equipment (ventilators, anaesthesia, monitoring, lights, pendants),Neonatal care and perinatal systems,Medical infrastructure, gas pipeline systems, and hospital planning, |
| LIFELOC TECHNOLOGIES, INC. | United States | Public Company | Hand-held fuel-cell breathalyzers (professional),Fixed and zero-tolerance screening stations (Sentinel, R.A.D.A.R.),Calibration systems, supplies, and accessories (EASYCAL, consumables), |
| MPD INC. | Australia | Private Company | Liquid milk & cream,Cheese (block, shredded, specialty),Butter, spreads & fats, |
| PSYCHEMEDICS CORPORATION | United States | Public Company | Employer job applicant and employee hair drug testing,Law enforcement and court-mandated testing,Schools and educational institutions, |
| SHIMADZU CORPORATION | Japan | Public Company | Analytical and Measuring Instruments,Medical Systems,Vacuum and Industrial Machinery, |
| SIEMENS HEALTHINEERS AG | Germany | Public Company | Imaging,Diagnostics,Varian (Oncology), |
UNILABS
UNILABS is a Swiss private laboratory services company established in 1987 with 1,897 employees.
EIKEN CHEMICAL CO., LTD.
Eiken Chemical Co., Ltd. is a Japanese public company founded in 1939 with 696 employees engaged in chemical manufacturing.
LABCORP
LabCorp is a United States-based public clinical laboratory company founded in 1995 with 66,385 employees providing diagnostic testing services.
QUEST DIAGNOSTICS INCORPORATED
Quest Diagnostics Incorporated is a publicly traded American diagnostic testing company established in 1967 with 51,500 employees.
ABBOTT
Abbott is a multinational American public company founded in 1888 with 115,000 employees operating in healthcare and diagnostics.
ORASURE TECHNOLOGIES INC.
OraSure Technologies Inc. is a United States public company founded in 1987 with 500 employees specializing in diagnostic testing products.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a large American public company founded in 1956 with 125,000 employees providing scientific and laboratory services.
DRäGERWERK AG & CO. KGAA
Drägerwerk AG & Co. KGaA is a German public company founded in 1889 with 16,033 employees specializing in medical and safety technology.
LIFELOC TECHNOLOGIES, INC.
LifeLoc Technologies, Inc. is a United States public company founded in 1983 with 37 employees.
MPD INC.
MPD Inc. is an Australian private company founded in 1977 with 40 employees.
PSYCHEMEDICS CORPORATION
PsycheMedics Corporation is a publicly traded American company founded in 1986 with 101 employees.
SHIMADZU CORPORATION
Shimadzu Corporation is a Japanese public company founded in 1875 with 14,649 employees manufacturing analytical and scientific instruments.
SIEMENS HEALTHINEERS AG
Siemens Healthineers AG is a German public healthcare technology company founded in 1896 with 72,369 employees.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise US market valuation ($4.6B in 2025) and verified growth projections through 2030, enabling accurate financial forecasting and investment decision-making for stakeholders.
- Regulatory Landscape Insights : Understand federal and state compliance requirements driving market expansion, including DOT, SAMHSA, and workplace safety mandates specific to the US market.
- Competitive Positioning Strategy : Identify market opportunities and competitive dynamics within the US drug screening sector to develop targeted business strategies and market entry approaches.
- Sector-Specific Demand Analysis : Analyze screening adoption rates across US industries including healthcare, transportation, manufacturing, and corporate sectors to identify high-growth segments and customer segments.
- Technology & Innovation Trends : Stay informed on emerging screening technologies and digital solutions gaining traction in the US market, supporting product development and service enhancement initiatives.
Frequently asked questions
What is the current size of the US drug screening market in 2025?
The US drug screening market is valued at $4,575.3 million in 2025, with strong growth anticipated through 2030.
What is the projected size of the US drug screening market by 2030?
The US drug screening market is forecast to reach $9,356.9 million by 2030, representing nearly a doubling of market value.
What is the CAGR for the US drug screening market?
The US drug screening market is growing at a compound annual growth rate (CAGR) of 15.4% from 2025 to 2030.
What factors are driving growth in the US drug screening market?
Growth in the US market is driven by regulatory compliance requirements, workplace safety mandates, substance abuse prevention initiatives, and technological advancements in screening methodologies.
Which technologies are most prevalent in the US drug screening market?
The US market utilizes immunoassay, chromatography, point-of-care testing, and increasingly automated and digitally integrated screening platforms.
RESEARCH METHODOLOGY
The study involved five major activities to estimate the current size of the drug screening market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for the study of the drug screening market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global drug screening market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (Hospital directors, Hospital Vice Presidents, Department heads, and Critical care specialists ) and supply side (such as C-level and D-level executives, technology experts, product managers, marketing and sales managers, among others) across five major regions North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
The following is a breakdown of the primary respondents:
BREAKDOWN OF PRIMARY PARTICIPANTS:
Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Tiers of companies are defined on the basis of their total revenues in 2023. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the drug screening market. These methods were also used extensively to estimate the size of various subsegments in the market.
The research methodology used to estimate the market size includes the following:
Data Triangulation
After arriving at the overall market size using the market size estimation processes, the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the drug screening market.
Market Definition
Drug and alcohol testing or drug screening refers to testing individuals for illegal abuse of drugs (including legal drugs such as prescription drugs) through the use of biological samples, such as urine, oral fluids/saliva, hair, blood, and sweat.
Key Stakeholders
- Drug screening product & solution providers (Including immunoassay kit manufacturers, confirmatory testing technology providers, breathalyzer and oral fluid testing device developers, rapid test and POCT vendors)
- Drug screening service providers (including Clinical laboratories, reference labs, forensic toxicology labs, workplace testing providers, on-site/mobile testing service companies)
- Healthcare providers (Hospitals, emergency departments, trauma centers, outpatient clinics, rehabilitation centers, pain management clinics, mental health and addiction treatment facilities)
- Workplace & employer organizations
- Law enforcement & public safety agencies
- Research & development (R&D) companies
- Judicial & legal system stakeholders
- Government & regulatory authorities
- Sports organizations & anti-doping agencies
- Payers & insurers
- Patients, employees & tested individuals
- Substance abuse treatment & rehabilitation providers
- Research & development (R&D) organizations
- Venture capitalists & private equity firms
- Advocacy groups & professional associations
- Investors & financial institutions
- Medical research laboratories & clinical trial organizations
- Academic institutions & training centers
- Technology & instrumentation providers
- Laboratory information & data management providers
- Sample collection & logistics providers
- Quality assurance, accreditation & certification bodies
- Consulting, training & compliance service provider
- Data analytics & emerging technology developers
Report Objectives
- To define, describe, and forecast the global drug screening market based on offering, sample type, drug type, end user, and region
- To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing market growth
- To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall drug screening market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To strategically analyze the market structure profile of the key players of the drug screening market and comprehensively analyze their core competencies
- To forecast the size of the market segments with respect to five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
- To track and analyze competitive developments such as product launches and enhancements, investments, partnerships, collaborations, acquisitions, expansions, product approval, and alliances in the drug screening market during the forecast period.
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:- Product Analysis: Product matrix, which gives a detailed comparison of the product portfolios of each company.
- Geographic Analysis: Further breakdown of Latin America, Europe, and the Middle East & Africa drug screening into specific countries
Get the Full Drug Screening Market Report
Full forecast, segment splits, and company analysis for all Drug Screening Market.
- Canada Drug Screening Market
- Germany Drug Screening Market
- France Drug Screening Market
- UK Drug Screening Market
- Italy Drug Screening Market
- Spain Drug Screening Market
- China Drug Screening Market
- Japan Drug Screening Market
- India Drug Screening Market
- Australia Drug Screening Market
- South Korea Drug Screening Market
- Brazil Drug Screening Market
- Mexico Drug Screening Market
- Saudi Arabia Drug Screening Market
- UAE Drug Screening Market
- South Africa Drug Screening Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report